Introduction
For life insurers, a major source of mortality risk mitigation is prudent underwriting at the time of application, which should ultimately reduce future claim costs. One way to refine the underwriting process is through measuring the impact of underwriting using insurance claims experience. Hypotheses are tested with the data and then improvements are made to the underwriting process. This process is best described using a control cycle as illustrated here:

Munich Re, US (Life) recently performed a deep dive into death claims stemming from its significant block of fully underwritten life insurance policies. Our focus was to better understand the drivers of mortality related to various causes of death.

In the following analysis we focused on the most common cause of death for our block, cancer (Table 1). Screening tools in the underwriting process are not very effective at identifying potential cancer mortality risk.

It should be noted that the focus of our research was on cancer mortality risk and not the incidence of cancer.

Dataset
The study was based on individual life policies, reinsured with Munich Re, with face amounts $100,000 and higher, that were issued from 1995 to the end of the second quarter 2014 and with exposure from 2006 to the end of the second quarter 2014. In all, there were 43 million life-years and $21.6 trillion of death benefit exposure in the study.

<table>
<thead>
<tr>
<th>Cause of death</th>
<th>Claim count</th>
<th>Count (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cancer</td>
<td>26,161</td>
<td>45.2%</td>
</tr>
<tr>
<td>Circulatory</td>
<td>13,086</td>
<td>22.6%</td>
</tr>
<tr>
<td>Accident</td>
<td>4,916</td>
<td>8.5%</td>
</tr>
<tr>
<td>Suicide</td>
<td>3,419</td>
<td>5.9%</td>
</tr>
<tr>
<td>Respiratory</td>
<td>2,526</td>
<td>4.4%</td>
</tr>
<tr>
<td>Nervous</td>
<td>2,472</td>
<td>4.3%</td>
</tr>
<tr>
<td>Digestive</td>
<td>1,170</td>
<td>2.0%</td>
</tr>
<tr>
<td>Mental and behavioral</td>
<td>1,096</td>
<td>1.9%</td>
</tr>
<tr>
<td>Infectious and parasitic</td>
<td>853</td>
<td>1.5%</td>
</tr>
<tr>
<td>Endocrine, nutritional and metabolic</td>
<td>653</td>
<td>1.1%</td>
</tr>
<tr>
<td>Crime</td>
<td>543</td>
<td>0.9%</td>
</tr>
<tr>
<td>Genitourinary</td>
<td>506</td>
<td>0.9%</td>
</tr>
<tr>
<td>Blood organs and immune mechanism</td>
<td>224</td>
<td>0.4%</td>
</tr>
<tr>
<td>All other causes</td>
<td>313</td>
<td>0.5%</td>
</tr>
<tr>
<td>Grand Total</td>
<td>57,938*</td>
<td></td>
</tr>
</tbody>
</table>

*3,609 claims of unknown causes are excluded from this display.

"Circulatory deaths are the major cause of death in the U.S. general population, largely due to the high proportion of circulatory deaths at ages 80 and above."
Key findings
Cancer is the most common cause of death in Munich Re's reinsured blocks of life insurance. This holds across decennial attained age groups except at the youngest (20-29) and oldest (80+) ages. A further breakdown by face amounts ($100,000-$999,000, over $1 million) and duration (one to three, and four plus) also confirms this. For face amounts over $1 million and durations one to three, cancer is the most common cause of death for ages 50 to 79. For the same face amounts and durations, accidental deaths are most common for ages 20 to 49.

Early durations
The proportion of cancer claims occurring in durations one to five increases across all face amount bands $100,000-$249,000, $250,000-$499,000, $500,000-$999,000 and over $1 million (Figure 1). This may be partially driven by anti-selection at higher face amounts. The majority of cancer claims (47 percent) occur in durations six to 10 while less than a fifth occur in the first five policy years. This trend is also seen for circulatory claims. Accidental and suicide claims tend to occur earlier, with 32 percent and 25 percent respectively in durations one to five. Figure 2 compares early duration to late duration mortality for accidents and cancer across face amount bands.

Cancer subtypes and face amounts
In the Munich Re block, cancer subtypes with the highest claims2 are lung (15.7 percent), colon (8.4 percent), breast (7.5 percent), eye/brain/central nervous system (7.1 percent), pancreas (7.8 percent), leukemia (6.9 percent) and genital organs (7.0 percent). Of these, eye/brain/central nervous system cancer is the one subtype that does not appear in the top seven for the U.S. general population.

Cancer mortality for face amounts over $1 million is better than for face amounts $100,000-$999,000, likely reflecting the positive impact of underwriting and socio-

2It is important to differentiate these mortality rates by cancer subtype from the incidence rates of different types of cancer in the U.S. general population.
economic factors. However, there are exceptions to this finding, notably for pancreatic and eye/brain/central nervous system (CNS) cancers (Figure 3).

Among male non-tobacco users, for face amounts $100,000-$999,000, lung and colon cancer have the highest subtype mortality in several issue age/duration cells. The occurrence of lung cancer claims points to possible smoking history misrepresentation or a consequence of smoker definitions prevalent in the industry. For the same group, pancreatic and eye/brain/CNS cancers show some evidence of elevated mortality for face amounts over $1 million (Table 2).

### Table 2: Cancer subtype with highest mortality by pricing cell

<table>
<thead>
<tr>
<th></th>
<th>$100k-$999k</th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Dur</td>
<td>20-29</td>
<td>30-39</td>
<td>40-49</td>
<td>50-59</td>
<td>60-69</td>
<td>70-79</td>
</tr>
<tr>
<td></td>
<td>20-29</td>
<td>30-39</td>
<td>40-49</td>
<td>50-59</td>
<td>60-69</td>
<td>70-79</td>
</tr>
<tr>
<td>Dure</td>
<td>Lung/Eye, Brain &amp; CNS</td>
<td>Colon</td>
<td>Lung</td>
<td>Lung</td>
<td>Lung</td>
<td>Lung/Leukemia</td>
</tr>
<tr>
<td>Dur</td>
<td>Colon/Leukemia</td>
<td>Colon</td>
<td>Colon</td>
<td>Lung</td>
<td>Lung</td>
<td>Lung</td>
</tr>
<tr>
<td>Dur</td>
<td>Colon</td>
<td>Colon</td>
<td>Colon</td>
<td>Colon</td>
<td>Lung</td>
<td>Lung</td>
</tr>
<tr>
<td>Dur</td>
<td>Lung</td>
<td>Eye, Brain &amp; CNS</td>
<td>Lung</td>
<td>Genital</td>
<td>Genital</td>
<td></td>
</tr>
</tbody>
</table>

### Table 2: Cancer subtype with highest mortality by pricing cell

<table>
<thead>
<tr>
<th></th>
<th>$1M+</th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Dur</td>
<td>20-29</td>
<td>30-39</td>
<td>40-49</td>
<td>50-59</td>
<td>60-69</td>
<td>70-79</td>
</tr>
<tr>
<td></td>
<td>20-29</td>
<td>30-39</td>
<td>40-49</td>
<td>50-59</td>
<td>60-69</td>
<td>70-79</td>
</tr>
<tr>
<td>Dure</td>
<td>Colon</td>
<td>Colon</td>
<td>Pancreas</td>
<td>Eye, Brain &amp; CNS</td>
<td>Lung</td>
<td>Pancreas</td>
</tr>
<tr>
<td>Dur</td>
<td>Eye, Brain &amp; CNS</td>
<td>Eye, Brain &amp; CNS</td>
<td>Eye, Brain &amp; CNS</td>
<td>Lung</td>
<td>Lung</td>
<td>Lung/Leukemia</td>
</tr>
<tr>
<td>Dur</td>
<td>Pancreas</td>
<td>Eye, Brain &amp; CNS</td>
<td>Pancreas</td>
<td>Lung</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Dur</td>
<td>Eye, Brain &amp; CNS</td>
<td>Lung</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

*Cells with fewer than five claims for every cancer subtype are left blank.*
Non-tobacco females for issue ages 60-79 at face amount $100,000 and higher also show high lung cancer mortality at many durations, raising questions about past smoking/tobacco use (Table 3).

**Excess mortality risk for smokers**
Smoking or tobacco use increases cancer risk, particularly for lung cancer (Figure 4).

### Table 3: Cancer subtype with highest mortality by pricing cell
**Female, non-tobacco decennial issue ages**

<table>
<thead>
<tr>
<th>100k-$999k</th>
<th>20-29</th>
<th>30-39</th>
<th>40-49</th>
<th>50-59</th>
<th>60-69</th>
<th>70-79</th>
<th>80+</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dur 1-5</td>
<td>Breast/Genital</td>
<td>Breast</td>
<td>Breast</td>
<td>Breast</td>
<td>Lung</td>
<td>Lung</td>
<td>Lung</td>
</tr>
<tr>
<td>Dur 6-10</td>
<td>Breast</td>
<td>Breast</td>
<td>Breast</td>
<td>Breast</td>
<td>Lung</td>
<td>Lung</td>
<td>Colon</td>
</tr>
<tr>
<td>Dur 11-15</td>
<td>Breast</td>
<td>Breast</td>
<td>Breast</td>
<td>Breast</td>
<td>Pancreas</td>
<td>Lung</td>
<td></td>
</tr>
<tr>
<td>Dur 16-20</td>
<td>Breast</td>
<td>Breast</td>
<td>Breast</td>
<td>Lung</td>
<td>Lung</td>
<td>Leukemia</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>$1M+</th>
<th>20-29</th>
<th>30-39</th>
<th>40-49</th>
<th>50-59</th>
<th>60-69</th>
<th>70-79</th>
<th>80+</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dur 1-5</td>
<td>Colon</td>
<td>Lung</td>
<td>Breast</td>
<td>Lung</td>
<td>Lung</td>
<td>Leukemia</td>
<td></td>
</tr>
<tr>
<td>Dur 6-10</td>
<td>Breast</td>
<td>Breast</td>
<td>Breast</td>
<td>Genital</td>
<td>Lung</td>
<td>Lung</td>
<td>Lung</td>
</tr>
<tr>
<td>Dur 11-15</td>
<td>Breast</td>
<td>Breast</td>
<td>Breast</td>
<td>Genital</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Dur 16-20</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Implications for underwriters and the way forward**

**Smoking status**
Our research demonstrates that smoking or tobacco use worsens mortality risk for all cancer subtypes. Verifying tobacco use is critical for accurate risk classification. Introduction of an accurate smoker prediction tool will

---

Figure 4: Gender specific tobacco to non-tobacco mortality

*Numbers in parentheses indicate claim numbers for non-tobacco and tobacco users.
be vital to combating anti-selection in the absence of a fluid-based nicotine screen.

Smoker definitions in a multi-class preferred, non-tobacco structure should be assessed for appropriateness. Adverse mortality impact of smoking may linger years after quitting smoking (Table 2, 3).

**Value of other underwriting tools**

In an accelerated underwriting environment, without the benefit of fluid testing like urine nicotine screen or blood, a well-constructed tele-app with drilldown questions to tease out smoking history and personal cancer history is a valuable underwriting tool.

Underwriters need to effectively use prescription drug databases, which are a valuable source of medication history, dosage, and physician specialty, to classify risk. Electronic health record (EHR) usage — now in a nascent stage — will become increasingly important in the absence of attending physician statements (APS).

**Foreign nationals**

Foreign nationals are becoming a bigger piece of a few insurers’ books of business. Early review of cause of death information has revealed cancer to be a sizable proportion of death claims in certain markets. Underwriters need to develop expertise in reviewing these cases based on information available from home countries, where medical records may not be as extensive as in the U.S.

**Conclusions**

With the trend towards automation, post-issue underwriting will be a cost-effective way for insurers to study the effectiveness of underwriting in the new paradigm. Pilot studies could be performed on samples to compare the effectiveness of new and traditional underwriting risk evaluation tools in screening for cancer risk. Business analytics should continuously monitor mortality trends in the automated underwriting space for differences with traditional underwriting.

Insurers should closely track their cancer claims experience by subtype, face amount band, and duration, to protect against the possibility of getting selected against, especially at the higher face amounts.

Cancer is an age-related disease and the aging population all but guarantees that we will see more applications from individuals who are adult cancer survivors and those who are at increasing risk for cancer because of aging itself. The use of markers such as PSA and CEA (carcinoembryonic antigen) in tandem with other underwriting tools will become important in the mature age population.

With regard to adult cancers, advances in immunotherapy continue to show progress — for example, in advanced melanoma, non-small cell lung cancers, etc. — that will likely expand to other tumor types. These advances bring optimism that people may live longer (quality of life preserved) and that cancer will be treated as a chronic disease rather than a terminal one.

**References**

2. [https://www.cdc.gov/nchs/data/nvsr/nvsr65/nvsr65_05.pdf](https://www.cdc.gov/nchs/data/nvsr/nvsr65/nvsr65_05.pdf)